Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

12.74 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 Next >
Analyst Ratings for Bausch & Lomb
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
9 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
Looking Into Bausch & Lomb's Return On Capital Employed
Via Benzinga
Bausch & Lomb's Return On Capital Employed Insights
Via Benzinga
Inflationary Factors And Slow Product Uptake Could Be Headwinds For Bausch + Lomb, Analyst Says
Via Benzinga
Recap: Bausch & Lomb Q1 Earnings
Via Benzinga
Analyst Expectations for Bausch & Lomb's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
The Latest Analyst Ratings for Bausch & Lomb
Via Benzinga
7 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
What 7 Analyst Ratings Have To Say About Bausch & Lomb
Via Benzinga
Expert Ratings for Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Analysts have provided the following ratings for Bausch & Lomb (NYSE:BLCO) within the last quarter: 
Via Benzinga
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Bausch & Lomb
Within the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Bausch & Lomb
  Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13
Benzinga Sam Bankman-Fried Arrested In The Bahamas 
Via Benzinga
Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits
More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Upgrades 
Via Benzinga
From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors
Formerly known as a "corporate raider," Carl Icahn is the founder and controlling shareholder of Icahn Enterprises, which is a large holding company with well diversified positions. 
Via Benzinga
BHC Stock Continues to Fall as Bausch Health Responds to Court Decision
Although Bausch Health promises to fight back against an unfavorable patent protection ruling, BHC stock is still hurting. 
Via InvestorPlace
Bausch Health (BHC) Stock Plunges 50% on Patent News
With Bausch Health losing a critical patent battle enabling its key drug to suffer generic competition, BHC stock veritably crumbled. 
Via InvestorPlace
Meta, Charter Communications, Southwest Airlines And Some Other Big Stocks Moving Lower On Thursday
Bausch Health Companies Inc. (NYSE: BHC) shares fell 50.3% to $4.3166 following reports of an order on a patent litigation over Xifaxan. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.